Year None20232022202120202019201820172016201520142013201220112010 Date Title View June 3, 2023 Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting May 24, 2023 Pyxis Oncology to Acquire Apexigen February 27, 2023 Apexigen Announces Review of Strategic Alternatives and Restructuring January 24, 2023 Apexigen Announces Approximately $2.8 Million Private Placement Financing January 19, 2023 Apexigen Announces New Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, at ASCO Gastrointestinal Cancers Symposium 2023
